论文部分内容阅读
目的探讨重组人血管内皮抑制素(恩度)治疗晚期胃癌的疗效和毒副反应。方法经病理学证实的晚期胃癌50例,随机分为两组,治疗组26例,采用恩度联合表阿霉素+亚叶酸钙+氟尿嘧啶+奥沙利铂(EOLF方案)化疗。对照组24例,采用单纯EOLF方案化疗。治疗2个疗程后评价疗效,每疗程评价毒性。结果治疗组有效率为57.7%,临床获益率为88.5%;对照组有效率为41.7%,临床获益率为62.5%;两组有效率及不良反应差异无统计学意义(P>0.05),临床获益率差异有统计学意义(P<0.05)。结论 EOLF方案对晚期胃癌有较好的近期疗效,联合恩度后可提高疗效,改善患者的生活质量,减轻不良反应,提高耐受性,值得进一步研究推广。
Objective To investigate the efficacy and side effects of recombinant human endostatin (Endostar) in the treatment of advanced gastric cancer. Methods Fifty patients with advanced gastric cancer confirmed by pathology were randomly divided into two groups. The treatment group (n = 26) was enrolled in combination with epirubicin + leucovorin + fluorouracil + oxaliplatin (EOLF) chemotherapy. Control group, 24 cases, using simple EOLF regimen chemotherapy. After 2 courses of treatment, the curative effect was evaluated, and the toxicity of each course was evaluated. Results The effective rate was 57.7% in the treatment group and 88.5% in the control group. The effective rate in the control group was 41.7% and the clinical benefit rate was 62.5%. There was no significant difference in the effective rate and adverse reactions between the two groups (P> 0.05) , The clinical benefit rate difference was statistically significant (P <0.05). Conclusion The EOLF regimen has a good short-term curative effect on advanced gastric cancer. Combined with Endometrioma can improve the curative effect, improve the quality of life of patients, reduce the adverse reactions and improve the tolerance. It is worth further study and promotion.